NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Clarametyx Biosciences

Clarametyx Biosciences

Private
Columbus, OhioHealthcare & Life Scienceshttps://clarametyx.com/

Last Round

Series A

Extension

Aug 4, 2025

Total Funding Raised

$55.59M

Company Overview

Clarametyx Biosciences is a biotechnology company that develops immune-enabling biologic therapies and vaccines targeting bacterial biofilms to treat severe persistent infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

monoclonal antibodybacterial biofilmantibiotic resistanceimmunotherapybiofilm disruptionsuperbug treatmentpreclinical biotechantigen targetingdrug discoveryhospital-acquired infectionHAIanti-infectivebiologicsnon-dilutive funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Clarametyx Biosciences Comparables

Compare Clarametyx Biosciences with similar companies based on industry and business-model similarity.

Clarametyx Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Trellis Bioscience
81%
Peptilogics
79%
Zaluvida Ventures
77%

Clarametyx Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionAug 4, 2025
Series A ExtensionMay 1, 2025
GrantJan 7, 2025
Series AJan 5, 2024
GrantApr 4, 2022
Grant
Aug 31, 2021

Key People

Founding team and executive leadership

Veronica Hall

Chief Operating Officer

Executive Team

Clarametyx Biosciences Investors

Notable investors and investment history

Clarametyx Biosciences investors
InvestorRounds
CARB-XGrant
Kineticos VenturesGrant
CincyTechSeries A Extension
Cystic Fibrosis FoundationSeries A
Rev1 VenturesSeed, Series A
Ohio Innovation FundSeries A
JobsOhioSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Raised Series A Extension with CincyTech and kineticos-amr-accelerator-fund-i.

  • Jan 28, 2025

    Douglas Thomson, Venture Partner at KAMRA, joins the board.

Clarametyx Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Clarametyx Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Clarametyx Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersColumbus, Ohio
Employee Range23
Year Founded2020
Last FundingAug 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.